Journal of vascular surgery. Venous and lymphatic disorders最新文献

筛选
英文 中文
Corrigendum.
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-11-12 DOI: 10.1016/j.jvsv.2026.102647
{"title":"Corrigendum.","authors":"","doi":"10.1016/j.jvsv.2026.102647","DOIUrl":"10.1016/j.jvsv.2026.102647","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102647"},"PeriodicalIF":3.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149379469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of cyanoacrylate closure alone versus combined high saphenous ligation and cyanoacrylate closure in large-diameter great saphenous veins. 大直径大隐静脉单用氰基丙烯酸酯缝合与高隐静脉结扎联合氰基丙烯酸酯缝合的远期疗效。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-28 DOI: 10.1016/j.jvsv.2026.102649
Hakan Baltacı, Zihni Mert Duman, Suna Yergin Taçyıldız, Celal Taçyıldız, Davut Azboy
{"title":"Long-term outcomes of cyanoacrylate closure alone versus combined high saphenous ligation and cyanoacrylate closure in large-diameter great saphenous veins.","authors":"Hakan Baltacı, Zihni Mert Duman, Suna Yergin Taçyıldız, Celal Taçyıldız, Davut Azboy","doi":"10.1016/j.jvsv.2026.102649","DOIUrl":"https://doi.org/10.1016/j.jvsv.2026.102649","url":null,"abstract":"<p><strong>Objective: </strong>Long-term evidence regarding the effectiveness of cyanoacrylate closure (CAC) in large-diameter great saphenous veins (GSVs) is limited. This study aimed to compare the long-term outcomes of CAC alone with those of combined high saphenous ligation and cyanoacrylate closure (HSL + CAC) for large-diameter GSV insufficiency.</p><p><strong>Methods: </strong>This single-center retrospective cohort study evaluated 198 extremities in 180 patients treated for symptomatic GSV insufficiency between January 2018 and December 2022 who had a preoperative GSV diameter of ≥8 mm. CAC was performed in 127 extremities and HSL + CAC in 71. Clinical and long-term duplex outcomes were compared using generalized estimating equation (GEE) models that accounted for within-patient clustering and prespecified confounders. Propensity score overlap weighting (PSOW) was used as a sensitivity analysis.</p><p><strong>Results: </strong>Long-term duplex follow-up data were available for 186 extremities (93.9%). HSL + CAC was associated with greater GSV occlusion (84.1% vs 65.8%; P = .007), less saphenofemoral junction (SFJ) reflux (5.8% vs 47.0%; P < .001), a lower postoperative Venous Clinical Severity Score (VCSS; 2.45 ± 2.04 vs 3.15 ± 1.89; P = .019), and greater VCSS improvement (3.45 ± 2.21 vs 1.47 ± 1.93; P < .001). Reoperation was performed in 8.7% of extremities treated with CAC alone but in none treated with HSL + CAC (P = .008). In adjusted GEE analyses, HSL + CAC was associated with a lower postoperative VCSS (β, -1.15; 95% CI, -1.71 to -0.59), greater GSV occlusion (OR, 3.05; 95% CI, 1.31-7.14), and less SFJ reflux (OR, 0.06; 95% CI, 0.015-0.223). PSOW estimates were consistent with the primary analyses. Complication rates were low and similar in both groups.</p><p><strong>Conclusions: </strong>In large-diameter GSVs, HSL + CAC was associated with better long-term anatomic and clinical outcomes than CAC alone, without an appreciable increase in complications. These findings suggest that adding HSL to CAC may improve long-term outcomes in selected patients with large-diameter GSVs.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102649"},"PeriodicalIF":3.1,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149287380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update of a living network meta-analysis comparing noncompounded 1% polidocanol endovenous microfoam (Varithena) ablation versus endovenous thermal ablation in chronic venous insufficiency. 一项活体网络荟萃分析的最新进展,比较非复合聚多醇1%静脉内微泡沫(Varithena)消融与静脉内热消融治疗慢性静脉功能不全。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-26 DOI: 10.1016/j.jvsv.2026.102648
Lowell S Kabnick, Omar L Esponda, Juan C Jimenez, Lina M Vargas, Larry Gache, Diana Frame, Candace Gunnarsson, Kathleen Ozsvath
{"title":"Update of a living network meta-analysis comparing noncompounded 1% polidocanol endovenous microfoam (Varithena) ablation versus endovenous thermal ablation in chronic venous insufficiency.","authors":"Lowell S Kabnick, Omar L Esponda, Juan C Jimenez, Lina M Vargas, Larry Gache, Diana Frame, Candace Gunnarsson, Kathleen Ozsvath","doi":"10.1016/j.jvsv.2026.102648","DOIUrl":"10.1016/j.jvsv.2026.102648","url":null,"abstract":"<p><strong>Objective: </strong>We previously published a network meta-analysis showing no statistically significant difference between commercially manufactured 1% polidocanol endovenous microfoam (PEM) and endovenous thermal ablation (ETA) for vein closure or deep vein thrombosis, when PEM was distinguished from physician-compounded foam. This living network meta-analysis updates the previous analysis comparing the effectiveness and safety of PEM ablation vs ETA for the primary treatment of adult patients with venous insufficiency caused by lower-extremity truncal vein incompetence.</p><p><strong>Methods: </strong>Systematic review searches following the prespecified protocol were conducted quarterly through March 2026. No changes were made to selection criteria. Vein closure, deep venous thrombosis, and ulcer healing were summarized as odds ratios (ORs) with 95% confidence intervals (CIs). A composite outcome of disease-specific quality of life (QoL) or symptom improvement scales was summarized with Hedges' g standardized mean difference.</p><p><strong>Results: </strong>The updated search yielded 507 new citations and 11 new eligible studies, for a total of 24 studies (235,413 patients). PEM was not statistically different from ETA for vein closure (OR, 0.71; 95% CI, 0.42-1.21). A sensitivity analysis at longest follow-up (mean, 28 months; range, 12-72 months) showed similar results (OR, 0.71; 95% CI, 0.45-1.11). There was no evidence of increased deep venous thrombosis risk with PEM vs ETA (OR, 0.83; 95% CI, 0.29-2.43). Post-treatment improvement in disease-specific QoL or venous insufficiency symptoms showed no statistically significant difference between PEM and ETA (Hedges' g standardized mean difference, 0.04; 95% CI, -0.16 to 0.25), though the network was not fully connected. Finally, ulcer healing data was limited, but an exploratory analysis found no evidence of a statistically significant difference.</p><p><strong>Conclusions: </strong>This living network meta-analysis update reinforced the original findings that 1% PEM is not statistically different from ETA for venous closure or deep venous thrombosis in the treatment of chronic venous insufficiency, and adds new preliminary information on outcomes relevant to the patient experience. There was no evidence of a statistically significant difference between PEM ablation and ETA for a composite of disease-specific QoL and symptom improvement, or for ulcer healing. The living approach maintains rigor and efficiently keeps evidence current as new studies emerge.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102648"},"PeriodicalIF":3.1,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149269377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 响应。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-21 DOI: 10.1016/j.jvsv.2026.102646
Felix Strobl, Agnes K Böhm, Leon Bruder
{"title":"Reply.","authors":"Felix Strobl, Agnes K Böhm, Leon Bruder","doi":"10.1016/j.jvsv.2026.102646","DOIUrl":"10.1016/j.jvsv.2026.102646","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102646"},"PeriodicalIF":3.1,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149238699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Noninvasive hemodynamics of nonthrombotic iliac vein lesions are disturbed in patients with a history of deep vein thrombosis. 有深静脉血栓病史的患者非血栓性髂静脉病变的非侵入性血流动力学受到干扰。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-19 DOI: 10.1016/j.jvsv.2026.102644
Ismael Z Assi, Drew J Braet, Sharika Bamezai, Luciano Delbono, Sonali Verma, David Williams, Thomas Wakefield, Andrea Obi, C Alberto Figueroa
{"title":"Noninvasive hemodynamics of nonthrombotic iliac vein lesions are disturbed in patients with a history of deep vein thrombosis.","authors":"Ismael Z Assi, Drew J Braet, Sharika Bamezai, Luciano Delbono, Sonali Verma, David Williams, Thomas Wakefield, Andrea Obi, C Alberto Figueroa","doi":"10.1016/j.jvsv.2026.102644","DOIUrl":"10.1016/j.jvsv.2026.102644","url":null,"abstract":"<p><strong>Objective: </strong>Nonthrombotic iliac vein lesions (NIVLs) are thought to be associated with deep vein thrombosis (DVT), yet most individuals with NIVL never develop thrombotic complications. This study assessed whether ultrasound-derived hemodynamic measurements differ between NIVL patients with and without a history of DVT, and whether these hemodynamic measurements better discriminate DVT history than percent stenosis alone.</p><p><strong>Methods: </strong>We performed a retrospective case control study of patients evaluated at a tertiary academic referral center between 2022 and 2025 who underwent pelvic venous duplex ultrasound imaging. Patients with left common iliac vein (LCIV) stenoses greater than 20% were included and categorized by history of left lower-extremity DVT. Exclusion criteria included concurrent DVT or previous venous stenting. Ultrasound images were digitized to obtain vessel diameters and spectral Doppler velocities in the iliac veins. Mean velocity, peak velocity, flow rate, shear rate, and ipsilateral and contralateral ratios were calculated. Continuous variables were compared using Welch t-tests, with statistical significance defined as P < .05.</p><p><strong>Results: </strong>Forty-five patients were included, comprising nine patients with previous DVT and 36 without. Among all metrics, velocity-based metrics at the compressed LCIV showed the strongest associations with a history of previous DVT, including ipsilateral velocity ratio [log<sub>2</sub> fold change (FC), -1.539; P = .007], peak velocity (log<sub>2</sub>FC, -0.999; P = .002), and mean velocity (log<sub>2</sub>FC, -0.989; P = .002). Differences in percent stenosis were statistically significant but less discriminative than velocity-based metrics (log<sub>2</sub>FC, 0.363; P = .033). Composite metrics such as flow rate and shear rate demonstrated weaker discrimination. Dimensionality reduction analysis revealed distinct clustering based on multivariate hemodynamic features between patients with and without a history of DVT.</p><p><strong>Conclusions: </strong>Among patients with NIVL, decreased velocity through the LCIV at the compression point was the strongest predictor of previous DVT, whereas percent stenosis was less discriminative. This study suggests that ultrasound-derived hemodynamic assessment can potentially provide a functional framework for risk stratification in patients with NIVL, but further prospective studies are needed to validate its clinical utility.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102644"},"PeriodicalIF":3.1,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic review of devices, designs, and trials for the treatment of deep venous reflux. 治疗深静脉反流的设备、设计和试验的系统综述。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-19 DOI: 10.1016/j.jvsv.2026.102643
Kwasi Ansere Ofori, Stephanie Li, Alyssa A Grimshaw, Rabih Chaer, Cassius Iyad Ochoa Chaar
{"title":"Systematic review of devices, designs, and trials for the treatment of deep venous reflux.","authors":"Kwasi Ansere Ofori, Stephanie Li, Alyssa A Grimshaw, Rabih Chaer, Cassius Iyad Ochoa Chaar","doi":"10.1016/j.jvsv.2026.102643","DOIUrl":"10.1016/j.jvsv.2026.102643","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Chronic venous insufficiency is driven primarily by venous reflux and affects nearly one-third of adults. Although superficial reflux is effectively treated with ablation, therapeutic options for deep venous reflux (DVR) remain limited. Despite decades of innovation, no prosthetic or bioprosthetic venous valve has achieved U.S. regulatory approval. We systematically reviewed device strategies, clinical and hemodynamic outcomes, complications, and barriers to translation for devices designed to treat DVR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We conducted an International Prospective Register of Systematic Reviews (CRD420251101761) of six databases from inception through February 2026, including in vivo animal and human studies evaluating prosthetic or bioprosthetic devices for DVR. Studies of native valve repair or autotransplantation were excluded. The primary outcome for human studies was clinical improvement, and secondary outcomes included patency, procedural complications, valvular function, and thrombosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 516 records identified, 15 met inclusion criteria: eight human and seven animal studies. Two principal strategies were identified: intraluminal valve restoration and external compression, with approximately 40% of devices delivered percutaneously or endovenously. In human studies, technical success ranged from 87.7% to 100%, patency from 67% to 100%, and perioperative complication rates from 0% to 44%, consisting primarily of bleeding, wound infection, and valve thrombosis. Valve occlusion occurred in up to 28% of animal implants and 18% to 22% of select human cohorts. Two perioperative deaths occurred in animal studies; none were reported in human studies. Among human studies, valve competency assessment methods varied substantially. Reported competency ranged from 0% to 92%, reflecting heterogeneity in imaging modalities and definitions. Discordance between anatomic patency, duplex-derived reflux reduction, and clinical improvement was frequently observed. In contemporary multicenter trial data, fewer than half of patients met predefined reflux-reduction end points despite high device patency and substantial clinical improvement, highlighting discordance between anatomic, hemodynamic, and patient-centered outcomes. By 1 year, pain had improved in 75% to 97% of patients; revised Venous Clinical Severity Scores decreased by 37% to 81%, with clinically meaningful (≥3-point) improvement in up to 84.6%; and ulcer healing ranged from 67% to 100%. Longer follow-up extended to 2 years in animal studies and up to 11 years in human series with various outcomes reported.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Several devices developed for DVR have demonstrated technical feasibility and symptom improvement. However, the risk of thrombosis, the marginal impact on valvular function, and the lack of standardization and selection of adequate end points in the measurement of results remain major b","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102643"},"PeriodicalIF":3.1,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A pilot study of the InVera Infusion Device: Twelve-month outcomes in the treatment of incompetent saphenous veins. InVera输液器的初步研究:治疗不功能隐静脉的12个月结果。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-19 DOI: 10.1016/j.jvsv.2026.102642
Imre Bihari, Stephen Madden, Nigel Phelan, Lowell S Kabnick
{"title":"A pilot study of the InVera Infusion Device: Twelve-month outcomes in the treatment of incompetent saphenous veins.","authors":"Imre Bihari, Stephen Madden, Nigel Phelan, Lowell S Kabnick","doi":"10.1016/j.jvsv.2026.102642","DOIUrl":"10.1016/j.jvsv.2026.102642","url":null,"abstract":"<p><strong>Objective: </strong>The InVera Infusion Device (IVID; InVera Medical) is a novel catheter designed for the delivery of sclerosant agents during nonthermal, nontumescent ablation of incompetent superficial truncal veins of the lower extremity. This device pilot study aimed to evaluate the technical success, safety, and 12-month clinical outcome.</p><p><strong>Methods: </strong>A single-center, prospective pilot study enrolled 10 patients with primary symptomatic axial reflux who underwent chemical ablation procedures with sclerosant delivery using the IVID. Primary outcomes assessed were technical procedural success, adverse events, revised Venous Clinical Severity Score (rVCSS), patient-reported outcomes based on a Heaviness, Achiness, Swelling, Throbbing, and Itching (HASTI) symptom questionnaire, and anatomical success rates from duplex ultrasound examination at baseline, 1 and 8 weeks, 3, 6, and 12 months postprocedure. Baseline and 12-month postprocedures were compared for both the rVCSS and the HASTI results using a paired t-test and a Wilcoxon signed-rank test respectively.</p><p><strong>Results: </strong>Technical procedural success was 100%. There were no device-related adverse events or serious adverse events including no deep vein thrombosis recorded throughout the follow-up period. Clinician assessed rVCSS and patient reported HASTI scores both showed statistically significant reductions from baseline to 12 months (adjusted P = .03 for both). Ultrasound-based anatomical assessment at 12 months demonstrated elimination of abnormal reflux and complete or partial occlusion in 90% of patients.</p><p><strong>Conclusions: </strong>The IVID provides a safe and effective technique for the delivery of sclerosant agents as part of the management of incompetent saphenous veins, demonstrating favorable 12-month anatomical, clinical and patient-reported outcomes in this pilot cohort.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102642"},"PeriodicalIF":3.1,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter regarding "Pelvic vein embolization using different embolic agents for the treatment of pelvic venous insufficiency: A systematic review and meta-analysis". 关于“盆腔静脉栓塞使用不同栓塞剂治疗盆腔静脉功能不全:系统回顾和荟萃分析”的信。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-17 DOI: 10.1016/j.jvsv.2026.102645
Romaric Loffroy
{"title":"Letter regarding \"Pelvic vein embolization using different embolic agents for the treatment of pelvic venous insufficiency: A systematic review and meta-analysis\".","authors":"Romaric Loffroy","doi":"10.1016/j.jvsv.2026.102645","DOIUrl":"10.1016/j.jvsv.2026.102645","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102645"},"PeriodicalIF":3.1,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Twelve-month results of cyanoacrylate closure in patients with venous leg ulceration. 氰基丙烯酸酯封闭治疗下肢静脉溃疡12个月的疗效。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-10-07 DOI: 10.1016/j.jvsv.2026.102635
Kathleen Gibson, Manjit Gohel, Ahmed Kayssi, Joseph Sabat, Nicolas Néaume, Leigh Ann O'Banion, Paul Gagne, Misaki Kiguchi, Neil M Khilnani, Raghu Kolluri, Nicholas Salkowski, Daniel J Denmark, Alun H Davies
{"title":"Twelve-month results of cyanoacrylate closure in patients with venous leg ulceration.","authors":"Kathleen Gibson, Manjit Gohel, Ahmed Kayssi, Joseph Sabat, Nicolas Néaume, Leigh Ann O'Banion, Paul Gagne, Misaki Kiguchi, Neil M Khilnani, Raghu Kolluri, Nicholas Salkowski, Daniel J Denmark, Alun H Davies","doi":"10.1016/j.jvsv.2026.102635","DOIUrl":"10.1016/j.jvsv.2026.102635","url":null,"abstract":"<p><strong>Background: </strong>Venous leg ulceration (VLU) is a major cause of patient distress and health care burden. Previous studies have highlighted the importance of early endovenous ablation of superficial venous reflux to expedite healing and prevent recurrence, but the optimal venous ablation modality is unclear.</p><p><strong>Objective: </strong>The aim of this study was to evaluate the effectiveness and safety of cyanoacrylate closure in patients with VLU.</p><p><strong>Design: </strong>A global, prospective, single-arm observational study was conducted in 17 centers across the United States and Europe. A total of 125 participants with VLU were included and treated with the VenaSeal closure system (Medtronic), in addition to standard wound therapy, including multilayered compression. Adjuvant treatments to varicosities, perforators or the subulcer plexus were left to the discretion of treating clinicians. The primary outcome was VLU healing through 12 months. Secondary outcomes included time to ulcer recurrence, anatomic vein closure, target limb adverse events (AEs), and changes in quality-of-life (QoL) measures.</p><p><strong>Results: </strong>One hundred twenty-five participants with VLU and saphenous vein reflux were enrolled. The mean ± standard deviation age was 67.9 ± 14.76 years, with 38.4% females and an overall mean body mass index of 32.4 ± 9.35. Concomitant foam sclerotherapy treatments were performed in 19.7% (31/157) of target veins. At 12 months, ulcer healing rate was 81.3%, and ulcer recurrence rate was 17.0%. The median time to ulcer healing was 92 days (95% confidence interval, 74-137). Anatomic vein closure was successful, with a closure rate of 86.6% among all treated veins through 12 months. Clinical events committee-adjudicated AE and serious AEs included: two granulomas, one hypersensitivity reaction, and four cases of phlebitis of the treated limb. Health care services used outside the index procedure yielded 0.12 adjunctive therapies per vein-year. Venous-specific and generic QoL scores showed sustained improvement compared with baseline scores.</p><p><strong>Conclusions: </strong>VenaSeal effectively eliminated saphenous reflux in patients with VLU. The ulcer healing rate was high, and the recurrence rate was low. Complication rates were also low and QoL improved.</p>","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":" ","pages":"102635"},"PeriodicalIF":3.1,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of the Caprini risk assessment score: 1991 to present: A living risk assessment tool 卡普里尼风险评估评分的演变:1991年至今:一个活生生的风险评估工具。
IF 3.1 2区 医学
Journal of vascular surgery. Venous and lymphatic disorders Pub Date : 2026-07-01 Epub Date: 2026-06-22 DOI: 10.1016/j.jvsv.2026.102484
Joann Lohr MD
{"title":"Evolution of the Caprini risk assessment score: 1991 to present: A living risk assessment tool","authors":"Joann Lohr MD","doi":"10.1016/j.jvsv.2026.102484","DOIUrl":"10.1016/j.jvsv.2026.102484","url":null,"abstract":"","PeriodicalId":17537,"journal":{"name":"Journal of vascular surgery. Venous and lymphatic disorders","volume":"14 4","pages":"Article 102484"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书